Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 11/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23303025 | 0.81 | CNR2 (0.46) | PTPN1CYP2D6CHRM1HTR2AHRH1 | |
| SCHEMBL16672183 | 0.78 | CALM1 (0.42) | NPC1MAPTRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL6957346 | 0.76 | PTPN1 (0.41) | PTPN1LOXL2GPR3MAPTNPSR1 | |
| SCHEMBL6735723 | 0.73 | HSP90AA1 (0.53) | PTPN1MAPTSMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL6735720 | 0.73 | HSP90AA1 (0.53) | PTPN1MAPTSMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL6735726 | 0.73 | HSP90AA1 (0.53) | PTPN1MAPTSMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL19225704 | 0.72 | GPR3 (0.46) | LOXL2GPR3MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL843065 | 0.72 | GPR3 (0.46) | GPR3NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL5792570 | 0.71 | L3MBTL1 (0.49) | GPR3NPC1L3MBTL1ALDH1A1LMNA | |
| SCHEMBL11731930 | 0.71 | PTPN1 (0.46) | PTPN1NPC1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683107-B2 | THERAPY OF METABOLISM DISORDERS | WYETH | 2004-01-27 | — | — | US | disclosed |
| US-20030073709-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2003-04-17 | — | — | US | disclosed |
| US-6451845-B1 | ANTIDIABETIC AGENTS | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020035272-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-21 | — | — | US | disclosed |
| US-6248764-B1 | ANTIDIABETIC AGENT; HYPOGLYCEMIC AGENT | AMERICAN HOME PRODUCTS CORPORATION | 2001-06-19 | — | — | US | disclosed |
| US-6103708-A | USEFUL IN TREATING METABOLIC DISORDERS RELATED TO INSULIN RESISTANCE OR HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073709-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | GPR119, INSR, FFAR3 | PTPN1 178/4885CYP2D6 315/4885CHRM1 2293/4885 |
| US-20020035272-A1 | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, FFAR3 | PTPN1 200/4885CYP2D6 270/4885CHRM1 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.